Raymed Labs Ltd.
Snapshot View

0.98 ▼0%

12 July 2021, 04:00:00 P.M.

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.raymedlab.com
Financial Indicators
Market Cap 0.42 Cr.
Earnings per share (EPS) -0.16 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share -4.80 Trailing Twelve Months Ending 2021-03
Price to Book Value -0.20 Calculated using Price: 0.98
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.43 Cr. 4,273,500 Shares
FaceValue 10
Company Profile

Raymed Labs was established in 1994 as a pharmaceutical company with emphasis on injectables with state of the art manufacturing facilities. the company is located at Dehradun Road, Saharanpur, UP. Manufacturing pharmaceutical products, as such, is a specialized job, however, manufacturing of injectables is even more difficult since they are normally given during a life saving situation thus their quality standards are much more stringent. Raymed’s quality quickly won the trusts of doctors and it established itself as one of the leading quality manufacturers of medicines in the area.

Raymed strives on a well organized management team of skilled and highly trained professionals from different streams.  This team contains chemists, pharmacists, marketing professionals with in-depth knowledge & requirements for human and animal products.

Products range:

  • RAMPICILLIN - Ampicillin, a semisynthetic penicillin
  • RAMPICLOX - Equal quantities of Ampicillin and Cloxacillin
  • RAMPIMOX - Equal quantities of Amoxycillin and Cloxacillin
  • RAMYKACIN - Amikacin Sulphate
  • OXYTETRACYCLINE - The most common Antibiotic in Veterinary Practice
  • RAMYFENAC-Diclofenac Sodium. It is a potent non steroidal Anti-inflammatory, Analgesic & Antipyretic for human use
  • RAMAMINE- Chlorpheniramine Maleate.  The most potent & effective Anti-histaminic for veterinary use
  • RAMYDEX-Dexamethasone Sodium Phosphate. Anti-inflammatory, Anti-allergic, Gluco-corticoid adjuvant with Antibiotic therapy
  • RAMYCIN-Gentamycin Sulphate
  • RAMYPINE - Atropin Sulphate.  The drug has anticholenergic effect in veterinary use.
  • RAMYCHLOR - Chloramphenicol
  • REALOPAR - Paracetamol
  • RAYVIL - Pheniramine Maleate
  • RAMALGIN-P - Phenylbutazone and Analgin with Lignocaine: A unique combination of highly effective analgesic, antispasmodic, anti-inflammatory & Antipyretic for veterinary use.
  • RAMYSCAB - Sulphur with Benzyl Benzoate in Lidocaine base: An ideal treatment of Scabies & other dermal problems in animals
  • RAMYVIT PLEX - Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B12 with Liver Extract:  crude injection and ideal treatment of Scabies & other dermal problems in animals

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
1 Month
+5.38%
3 Month
+5.38%
6 Month
+1.03%
1 Year
+1.03%
2 Year
-57.21%
5 Year
-67.00%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%)
Return on Capital Employed (%) -9.22 -12.72 -13.45 -7.11 -15.55 -26.39 -41.34 -58.42 -105.49
Return on Assets (%) -9.40 -11.47 -12.03 -6.08 -12.90 -17.98 -20.71 -20.01 -21.34

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds -2 -2 -2 -2 -2 -2 -2 -2 -2
Non Curr. Liab.
Curr. Liab. 2 2 2 2 2 2 2 2 2
Minority Int.
Equity & Liab. 1 1 0 0 0 0 0 0 0
Non Curr. Assets 0 0 0 0 0 0 0 0 0
Curr. Assets 0 0 0 0 0 0 0 0 0
Misc. Exp. not W/O
Total Assets 1 1 0 0 0 0 0 0 0

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 0
Other Income 0 0 0 0 0 0 0
Total Income 0 0 0 0 0 0 0 0
Total Expenditure 0 0 0 0 0 0 0 0 0
PBIDT 0 0 0 0 0 0 0 0
Interest 0
Depreciation 0 0 0 0 0 0 0
Taxation
Exceptional Items 0 0 0 0 0 0 0 0
PAT 0 0 0 0 0 0 0 0 0

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 0
Cash Fr. Inv. 0
Cash Fr. Finan. 0 0 0 0
Net Change 0 0 0
Cash & Cash Eqvt 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 28.36 28.36 28.36 28.36 28.36 28.36 28.36 28.36 28.36
Public 71.64 71.64 71.64 71.64 71.64 71.64 71.64 71.64 71.64
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
Raymed Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Mon, 19 Jul 2021
Appointment of Company Secretary and Compliance Officer
Intimation for the appointment of Company Secretary and Compliance Officer
Thu, 15 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Ajai Goyal
Designation :- Managing Director / Whole Time Director

Technical Scans View Details

No Scans Found

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%